[{"id":"d479d7a5-69ba-49e5-93fa-ae230286eb90","acronym":"CL1-95029-001","url":"https://clinicaltrials.gov/study/NCT05162755","created_at":"2021-12-17T17:31:24.245Z","updated_at":"2025-02-25T14:02:39.100Z","phase":"Phase 1","brief_title":"S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers","source_id_and_acronym":"NCT05162755 - CL1-95029-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026) • S95029 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/19/2025","study_completion_date":" 06/19/2025","last_update_posted":"2025-02-19"},{"id":"7f903bf7-9fc1-43cc-8ff0-c5b59af057ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04672434","created_at":"2021-01-19T20:44:53.857Z","updated_at":"2024-07-02T16:35:06.328Z","phase":"Phase 1","brief_title":"Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT04672434","lead_sponsor":"Symphogen A/S","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S95024 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/19/2020","start_date":" 11/19/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-02"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"}]